Nesfatin-1: Its role in the diagnosis and treatment of obesity and some psychiatric disorders

Methods in Molecular Biology

Volumn 963, Issue , 2013, Pages 327-338

  Shimizu, Hiroyuki ^a   Mori, Masatomo ^b  

^a TAKASAKI UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Calcium; EF hand; Nesfatin 1; Nucleobindin 2; Obesity

Indexed keywords

ANTIOBESITY AGENT; INSULIN; LEPTIN; MELANIN CONCENTRATING HORMONE; MELANOCORTIN; MESSENGER RNA; NESFAIN 1 RECEPTOR AGONIST; NESFATIN 1; NESFATIN 1 RELATED PEPTIDE; NUCLEOBINDIN 2; PEPTIDE; PROOPIOMELANOCORTIN; UNCLASSIFIED DRUG; CALCIUM BINDING PROTEIN; DNA BINDING PROTEIN; NERVE PROTEIN; NUCLEOBINDIN;

AMINO ACID SEQUENCE; ANOREXIA; APPETITE; BODY WEIGHT GAIN; DRUG MEGADOSE; FEEDING BEHAVIOR; FOOD INTAKE; GASTROINTESTINAL TRACT FUNCTION; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; MENTAL DISEASE; NONHUMAN; OBESITY; ANIMAL; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; PSYCHOLOGICAL ASPECT; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; APPETITE; CALCIUM-BINDING PROTEINS; DNA-BINDING PROTEINS; FEEDING BEHAVIOR; HUMANS; MENTAL DISORDERS; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; OBESITY;

EID: 84878748689     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-230-8_20     Document Type: Chapter

References (33)

1. Shimizu H, Mori M (2005) The brain-adipose axis. Nutr Neurosci 8:7–20.
2. Shimizu H, Tsuchiya T, Sato N et al (1998) Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 21:1470–1474.
3. Oh-I S, Shimizu H, Satoh T et al (2006) Identi fication of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 443:709–712.
4. Yamada M, Horiguchi K, Umezawa R et al (2010) Troglitazone, a ligand of peroxisome proliferator-activated receptor-g, stabilizes NUCB2 (Nesfatin) mRNA by activating the ERK1/2 pathway: isolation and characterization of the human NUCB2 gene. Endocrinology 151:2494–2503.
5. Brailoiu GC, Dun SL, Braoiu E et al (2007) Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 148:5088–5094.
6. Merali Z, Cayer C, Kent P et al (2008) Nesfatin-1 increases anxiety- and fear-related behaviors in the rat. Psychopharmacology (Berl) 201:115–123.
7. Pan W, Hsuchou H, Kastin AJ (2007) Nesfatin-1 crosses the blood–brain barrier without saturation. Peptides 28:2223–2228.
8. Price TO, Samson WK, NiehoffML et al (2007) Permeability of the blood–brain barrier to a novel satiety molecule nesfatin-1. Peptides 28:2372–2381.
9. Oh-I S, Shimizu H, Satoh T et al (2005) Molecular mechanisms associated with leptin resistance: n-3 polyunsaturated fatty acids induce alterations in the tight junction of the brain. Cell Metab 1:331–341.
10. Shimizu H, Oh-I S, Okada S et al (2009) Nesfatin-1: an overview and future clinical application. Endocr J 56:537–543.
11. Shimizu H, Oh-I S, Hashimoto K et al (2009) Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 150:662–671.
12. Kohno D, Nakata M, Maejima Y et al (2008) Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology 149:1295–1301.
13. Price CJ, Hoyda TD, Samson WK et al (2008) Nesfatin-1 in fluences the excitability of paraventricular nucleus neurons. J Neuroendocrinol 20:245–250.
14. Douglas AJ, Johnstone LE, Leng G (2007) Neuroendocrine mechanism of change in food intake during pregnancy: a potential role for brain oxytocin. Physiol Behav 91:352–365.
15. Price CJ, Samson WK, Ferguson AV (2008) Nesfatin-1 inhibits NPY neurons in the arcuate nucleus. Brain Res 1230:99–106.
16. InhoffT, Mönnikes H, Noetzel S et al (2008) Desacyl ghrelin inhibits the orexigenic effect of peripherally injected ghrelin in rats. Peptides 29:2159–2168.
17. Fort P, Salvert D, Hanriot L et al (2008) The satiety molecule nesfatin-1 is co-expressed with melanin concentrating hormone in tuberal hypothalamic neurons of the rat. Neuroscience 155:174–178.
18. Foo KS, Brismar H, Broberger C (2008) Distribution and neuropeptide coexistence of nucleobindin-2 mRNA/nesfatin-like immunoreactivity in the rat CNS. Neuroscience 156:563–579.
19. Stengel A, Goebel M, Yakubov I et al (2009) Identi fication and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 150:232–238.
20. Macro JA, Dimaline R, Dockray GJ (1996) Identi fication and expression of prohormoneconverting enzymes in the rat stomach. Am J Physiol 270:G87–G93.
21. Date Y, Murakami N, Toshinai K et al (2002) The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123: 1120–1128.
22. Shimizu H, Ohsaki A, Oh-I S et al (2009) A new anorexigenic protein, nesfatin-1. Peptides 30:995–998.
23. Gonzalez R, Tiwari A, Unniappan S (2009) Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem Biophys Res Commun 381:643–648.
24. 2+ in flux through L-type channels in mouse islet b-cells. Endocr J 58:305–313.
25. Gonzalez R, Perry RL, Gao X et al (2011) Nutrient responsive nesfatin-1 regulates energy balance and induces glucose-stimulated insulin secretion in rats. Endocrinology 152:3628–3637.
26. Riva M, Dekker M, Voss U et al (2011) Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects. Cell Tissue Res 346:393–405.
27. Tsuchiya T, Shimizu H, Yamada M et al (2010) Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in nonobese males. Clin Endocrinol 73:484–490.
28. Lo QC, Wang HY, Chen X et al (2010) Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrientrelated fluctuation of nesfatin-1 level in normal humans. Regul Pept 8:72–77.
29. Zhang Z, Li L, Yang M et al (2012) Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 120:91–95.
30. Aydin S, Dag E, Ozkan Y et al (2009) Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders. Mol Cell Biochem 32:49–56.
31. Ari M, Ozturk OH, Bez Y et al (2010) High plasma nesfatin-1 level in patients with major depressivedisorder. ProgNeuropsychopharmacol Biol Psychiatry 35:497–500.
32. Heyms field SB, Greeberg AS, Fujioka K et al (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282:1568–1575.
33. Tan BK, Hallschmid M, Kern W et al (2011) Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/ NUCB-2 resistance and implications for obesity treatment. J Clin Endocrinol Metab 96:E669–E673.